Analysts forecast that IsoRay, Inc. (NASDAQ:ISR) will post sales of $1.82 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for IsoRay’s earnings. The lowest sales estimate is $1.70 million and the highest is $1.94 million. IsoRay posted sales of $1.60 million during the same quarter last year, which suggests a positive year-over-year growth rate of 13.8%. The business is scheduled to report its next earnings results on Tuesday, September 24th.
According to Zacks, analysts expect that IsoRay will report full year sales of $7.22 million for the current year, with estimates ranging from $7.10 million to $7.33 million. For the next year, analysts forecast that the firm will report sales of $10.37 million, with estimates ranging from $10.36 million to $10.37 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover IsoRay.
IsoRay (NASDAQ:ISR) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The company had revenue of $1.92 million during the quarter, compared to the consensus estimate of $1.92 million.
ISR traded down $0.04 during trading on Friday, hitting $0.34. The company had a trading volume of 49,604 shares, compared to its average volume of 152,370. IsoRay has a one year low of $0.27 and a one year high of $0.62. The stock has a 50-day moving average of $0.41.
IsoRay Company Profile
IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.
Read More: What is the definition of a trade war?
Get a free copy of the Zacks research report on IsoRay (ISR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.